List of Excipients in Branded Drug CARDINAL HEALTH ANTISEPTIC SKIN CLEANSER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	CARDINAL HEALTH ANTISEPTIC SKIN CLEANSER	chlorhexidine gluconate 2%	0116-0113	CITRIC ACID MONOHYDRATE
Xttrium Laboratories Inc	CARDINAL HEALTH ANTISEPTIC SKIN CLEANSER	chlorhexidine gluconate 2%	0116-0113	COCO DIETHANOLAMIDE
Xttrium Laboratories Inc	CARDINAL HEALTH ANTISEPTIC SKIN CLEANSER	chlorhexidine gluconate 2%	0116-0113	HYDROXYETHYL CELLULOSE
Xttrium Laboratories Inc	CARDINAL HEALTH ANTISEPTIC SKIN CLEANSER	chlorhexidine gluconate 2%	0116-0113	LAURAMINE OXIDE

Cardinal Health Antiseptic Skin Cleanser: Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: August 16, 2026

Cardinal Health Antiseptic Skin Cleanser is a chlorhexidine gluconate, or CHG, topical cleanser positioned for preoperative, clinical, and institutional skin antisepsis. Its commercial value depends less on novel active-ingredient protection than on formulation robustness, skin tolerability, packaging, hospital procurement, and supply reliability. The principal excipient strategy is to stabilize CHG, improve wetting and rinseability, control foam, maintain skin feel, and support a low-cost private-label product.

What active ingredient is used in Cardinal Health Antiseptic Skin Cleanser?

Cardinal Health Antiseptic Skin Cleanser is generally identified as a 4% chlorhexidine gluconate topical cleanser. The active is an established broad-spectrum antiseptic used against many gram-positive and gram-negative bacteria. It is not a systemic drug and has no biosimilar pathway.

Typical product positioning includes:

Attribute	Product profile
Active ingredient	Chlorhexidine gluconate, commonly 4%
Dosage form	Topical liquid cleanser
Route	Cutaneous use
Primary settings	Hospitals, surgery centers, clinics, long-term care, home health
Primary applications	Preoperative washing, patient bathing, healthcare antisepsis
Product type	OTC or institutional topical drug, depending on label and market
Competitive products	Hibiclens, generic 4% CHG cleansers, povidone-iodine, alcohol-based antiseptics
Biosimilar exposure	None
Main commercial barriers	Regulatory labeling, safety controls, hospital contracts, manufacturing consistency

The exact excipient composition and concentration should be tied to the applicable Cardinal Health NDC and current package insert. Publicly available CHG cleanser labels commonly identify purified water, gluconolactone, lauramine oxide, poloxamer 237, PEG-7 glyceryl cocoate, fragrance, and colorants among the inactive ingredients. DailyMed should be used as the controlling source for the marketed presentation.[1]

What excipients are used in 4% chlorhexidine cleansers?

The excipients in a conventional 4% CHG cleanser perform formulation and usability functions rather than therapeutic functions.

Excipient or excipient class	Primary function	Commercial relevance
Purified water	Vehicle	Controls cost, viscosity, and manufacturing processability
Gluconolactone	pH adjustment or buffering support	Helps maintain formulation compatibility and product stability
Lauramine oxide	Surfactant and foam aid	Improves soil removal and consumer perception
Poloxamer 237	Nonionic surfactant and solubilizing aid	Supports wetting, cleansing, and formulation uniformity
PEG-7 glyceryl cocoate	Emollient and refatting agent	Reduces harsh skin feel and supports repeat-use tolerability
Fragrance	Odor masking and sensory differentiation	Can improve acceptance but creates sensitization and compliance risks
Colorant	Product identification and consumer appeal	Adds branding value but increases regulatory and quality complexity

CHG is cationic. Its compatibility profile is therefore central to excipient selection. Anionic surfactants, soaps, some polymers, and certain preservatives can reduce antimicrobial activity through binding, precipitation, or chemical incompatibility. A formulation that cleans well but reduces free CHG concentration can create a clinically and commercially unacceptable product.

How should the excipient strategy be optimized?

The preferred strategy is a low-complexity, nonionic system that preserves CHG availability while improving tolerability.

1. Protect antimicrobial activity

Formulators should screen every surfactant, polymer, fragrance component, dye, and processing aid for interaction with cationic CHG. The key tests are:

• Available or free CHG concentration over shelf life
• Antimicrobial activity after aging
• Precipitation, haze, or phase separation
• Compatibility with hard water and hospital water systems
• Interaction with dispensing pumps and closure materials
• Compatibility after freeze-thaw and elevated-temperature storage

Nonionic surfactants such as poloxamers are generally more attractive than anionic surfactants for CHG systems. The formulation should avoid unnecessary excipients that add no measurable performance benefit.

2. Improve skin tolerability

Repeated hospital bathing can produce dryness, irritation, and poor compliance. PEG-7 glyceryl cocoate or comparable refatting excipients can improve after-feel without materially impairing cleansing. The balance is narrow: excessive emollient loading can reduce rinseability, leave residue, or interfere with CHG deposition.

A differentiated product could use:

• Lower-irritancy fragrance-free versions
• Reduced-dye or dye-free variants
• Humectant or refatting systems
• Lower-foam formulations for surgical preparation
• Separate formulations for daily bathing and one-time preoperative use

Skin tolerability claims require substantiation. A more expensive excipient system is commercially justified only if it produces measurable reductions in irritation, improved repeat-use acceptance, or stronger institutional adherence.

3. Control foam and rinseability

Foam is a sensory signal, not proof of antimicrobial performance. Excessive foam can increase rinse time, complicate operating-room workflows, and create packaging problems. The best institutional formulation may use moderate foam with rapid wetting and clean rinsing.

For home-use or retail channels, greater foam and a richer skin feel may increase consumer acceptance. This creates a potential channel-specific portfolio:

Channel	Preferred formulation attributes
Operating room	Low residue, controlled foam, fast rinse, broad packaging compatibility
Inpatient bathing	Mild skin feel, moderate foam, large-volume packaging
Outpatient clinics	Compact packaging, clear directions, low leakage risk
Retail	Sensory appeal, fragrance option, consumer-friendly dispensing
Home health	Mildness, easy dosing, tamper evidence, simple labeling

What FDA regulatory status applies to Cardinal Health Antiseptic Skin Cleanser?

FDA status depends on the product’s labeled indication, active concentration, marketing pathway, and applicable OTC monograph order.

CHG has a long history of use in healthcare antisepsis, but FDA treatment of antiseptic active ingredients differs by use category. FDA has evaluated CHG in consumer antiseptic wash products and healthcare antiseptic products separately. A product marketed for preoperative skin preparation, healthcare personnel hand antisepsis, patient bathing, or general consumer cleansing can face different evidentiary and labeling requirements.[2][3]

The critical regulatory issues are:

1. Whether the product is marketed under an applicable OTC monograph order.
2. Whether the labeled indication matches the authorized category.
3. Whether the product makes claims beyond cleansing and antisepsis.
4. Whether the manufacturing site complies with current good manufacturing practice.
5. Whether the formulation, packaging, and labeling match the listed product.
6. Whether warnings address ocular, otic, mucosal, and neonatal exposure risks.

CHG products require prominent safety controls because serious eye injury and ototoxicity have been reported following inappropriate exposure. Product labels typically direct users to avoid the eyes, ears, mouth, and other sensitive areas.[1][4]

What patents protect Cardinal Health Antiseptic Skin Cleanser?

No prominent composition-of-matter patent is expected to protect a conventional 4% CHG cleanser. Chlorhexidine and many basic CHG cleansing formulations are old technologies. The commercial estate is more likely to depend on:

• Formulation patents
• Packaging patents
• Dispensing systems
• Preoperative application kits
• Impregnated cloths or sponges
• Manufacturing processes
• Stability improvements
• Combination products
• Trade secrets covering process controls and supplier specifications

Cardinal Health is primarily a healthcare distribution and services company rather than the originator of CHG technology. The product may be manufactured by a contract or private-label supplier. Patent ownership and litigation exposure therefore depend on the exact NDC, manufacturer, formulation, and package configuration.

Are Orange Book patents likely to protect the product?

For a conventional topical CHG cleanser, Orange Book patent exposure is likely to be limited. The Orange Book lists approved drug products and associated patents and exclusivities for qualifying applications.[5] A private-label OTC cleanser marketed under an OTC monograph pathway would not normally have the same Orange Book patent profile as a new prescription drug approved under an NDA.

Potential patent risk is more likely to arise from:

• A patented delivery device
• A patented impregnated wipe or sponge
• A patented combination with another antiseptic
• A formulation with a specific stability or deposition profile
• A patented kit used in surgery or catheter care

Paragraph IV challenges are therefore not the primary generic-entry issue for a standard CHG cleanser. Market entry is more likely to occur through an alternative manufacturer, an OTC monograph-compliant product, or a private-label supply agreement.

When does Cardinal Health Antiseptic Skin Cleanser lose exclusivity?

The product does not appear to have a conventional prescription-drug exclusivity clock comparable to a new chemical entity. Chlorhexidine is an established active ingredient, and generic or private-label competition can arise when a manufacturer can satisfy regulatory, quality, supply, and procurement requirements.

Exclusivity analysis should separate four categories:

Exclusivity type	Relevance
New chemical entity exclusivity	Not applicable to established CHG
NDA clinical exclusivity	Generally not the primary framework
Patent exclusivity	Potentially relevant only to specific formulations, kits, or devices
Commercial or contractual exclusivity	Often important in private-label and hospital supply arrangements

The practical loss of exclusivity may occur when a competing supplier wins a group purchasing organization contract, qualifies an alternate manufacturing site, or offers a lower-cost product with equivalent clinical workflow performance.

What commercial opportunities exist for CHG cleanser excipients?

The largest opportunities are product segmentation and institutional cost reduction.

Fragrance-free and low-irritancy formulations

A fragrance-free formulation can target hospitals seeking lower exposure to sensitizers and patients requiring frequent bathing. The commercial case depends on irritation testing, user acceptance, and procurement standards.

CHG-compatible emollient systems

A controlled refatting system can differentiate the product from low-cost generic cleansers. The strongest claims would relate to skin feel, dryness scores, or repeat-use tolerability rather than unsupported superiority in antimicrobial activity.

Ready-to-use wipes and cloths

Pre-moistened CHG cloths can reduce nursing time, improve dose consistency, and limit contamination during bedside bathing. This format may have greater commercial value than a liquid cleanser because it integrates product, dosing, and workflow.

Surgical kits and procedure-specific packaging

A cleanser packaged with applicators, towels, gloves, or procedural instructions can increase average selling price and create switching costs. Device and kit patents may be more relevant than liquid formulation patents.

Sustainable packaging

Opportunities include:

• Reduced-plastic bottles
• Recyclable closures
• Concentrated refill systems where safe and compliant
• Larger institutional containers
• Packaging designed to reduce residual product waste

Packaging changes must preserve CHG compatibility, dose accuracy, microbial control, and transport stability.

How strong is the patent estate for Cardinal Health Antiseptic Skin Cleanser?

The likely patent estate is weak for the basic liquid formulation and stronger for differentiated delivery formats.

Asset type	Expected protection strength	Main reason
4% CHG active ingredient	Low	Established active with extensive prior art
Conventional liquid cleanser	Low to moderate	Limited novelty unless stability or deposition is unusual
Specific excipient ratio	Moderate	Patentability depends on unexpected technical effect
Pre-moistened cloth	Moderate to strong	Format, substrate, loading, and packaging claims may apply
Applicator or kit	Moderate to strong	Device and combination claims can create barriers
Manufacturing process	Moderate	Trade secret protection may exceed patent value
Hospital contract	Commercially strong but time-limited	Procurement and supply agreements can delay switching

A credible formulation patent would need more than a routine substitution of one surfactant for another. It would need evidence of an unexpected result, such as preserved CHG activity with materially improved skin tolerability, superior stability, reduced residue, or improved antimicrobial deposition.

Which companies compete with Cardinal Health Antiseptic Skin Cleanser?

The relevant competitive set includes:

• Mölnlycke Health Care, including CHG bathing products
• Becton, Dickinson and Company, including antiseptic preparation products
• Mölnlycke and other hospital-supply companies offering CHG cloths
• Mölnlycke’s Mepilex-related hospital channel presence, although not all products compete directly
• Medline Industries
• 3M and Solventum-related skin-preparation products
• PDI
• Medtronic and other procedure-kit suppliers
• Generic and private-label manufacturers of 4% CHG cleansers
• Povidone-iodine and alcohol-based antiseptic suppliers

The closest direct competitors are generic 4% CHG liquid cleansers and CHG-impregnated cloths. Alcohol and povidone-iodine products compete on speed, indication, residue, drying time, and procedure workflow rather than formulation equivalence.

What generic launch risks exist?

Generic-entry risk is high at the molecule and dosage-form level but lower at the account level.

A competitor can launch a comparable cleanser if it can:

1. Source pharmaceutical-grade CHG.
2. Demonstrate formulation stability.
3. Meet microbial and quality specifications.
4. Validate packaging compatibility.
5. Comply with FDA labeling requirements.
6. Establish adequate manufacturing capacity.
7. Obtain hospital and group purchasing organization approval.
8. Maintain uninterrupted supply.

The principal barriers are operational rather than patent-based. Hospitals may require vendor qualification, clinical review, product standardization, and conversion testing. These requirements can slow substitution even when the product itself has limited patent protection.

What manufacturing and intellectual-property barriers matter most?

Manufacturing controls include:

• Accurate CHG assay and uniformity
• Control of pH and viscosity
• Microbial limits
• Preservative or antimicrobial effectiveness where applicable
• Raw-material consistency
• Container-closure integrity
• Pump and cap compatibility
• Batch-to-batch color and fragrance consistency
• Stability under shipping and storage conditions

Trade secrets may cover mixing order, shear conditions, surfactant incorporation, deaeration, filling, and cleaning validation. These controls can produce meaningful commercial advantages without appearing in public patent databases.

Key Takeaways

• Cardinal Health Antiseptic Skin Cleanser is generally positioned as a 4% CHG topical cleanser.
• The excipient strategy centers on nonionic surfactants, foam control, pH management, emollience, and CHG compatibility.
• A conventional CHG liquid has limited composition-of-matter or Orange Book patent protection.
• Formulation, applicator, cloth, kit, and packaging patents are more commercially relevant.
• FDA status depends on the labeled use and applicable OTC antiseptic regulatory pathway.
• The strongest commercial opportunities are fragrance-free products, skin-tolerability formulations, ready-to-use cloths, procedure kits, and sustainable institutional packaging.
• Generic competition is more likely to be constrained by hospital procurement, quality systems, supply reliability, and contracts than by patents.

FAQs

Is Cardinal Health Antiseptic Skin Cleanser the same as Hibiclens?

Both products are commonly associated with 4% CHG cleansing formulations, but they are not necessarily identical. Inactive ingredients, manufacturing sites, packaging, labeling, and quality specifications can differ.

Can anionic surfactants be used with chlorhexidine gluconate?

Anionic surfactants require careful evaluation because they can interact with cationic CHG and reduce available antimicrobial activity. Nonionic surfactants are generally more suitable starting points.

Is a CHG cleanser protected by a patent?

The basic 4% CHG liquid cleanser is unlikely to have meaningful active-ingredient patent protection. Specific formulations, wipes, applicators, and kits may have separate patent rights.

What is the best excipient for reducing CHG skin irritation?

No single excipient is universally optimal. Controlled emollient systems such as PEG-7 glyceryl cocoate may improve skin feel, but the final formulation must preserve antimicrobial activity, rinseability, stability, and label compliance.

Are biosimilars relevant to Cardinal Health Antiseptic Skin Cleanser?

No. CHG cleanser is a small-molecule topical drug product, not a biologic. Competition occurs through generic, OTC, private-label, and institutional supply channels rather than biosimilar substitution.

References

1. DailyMed. (n.d.). Chlorhexidine gluconate 4% topical cleanser labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 81 Fed. Reg. 61106.
3. U.S. Food and Drug Administration. (2019). Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register.
4. U.S. Food and Drug Administration. (n.d.). Chlorhexidine gluconate: Drug safety communication regarding rare but serious allergic reactions.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.